Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?

Fareed Khawaja; Roy F. Chemaly

doi:10.1038/s41409-022-01616-7

Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?

Fareed Khawaja, Roy F. Chemaly

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	701-702
Number of pages	2
Journal	Bone marrow transplantation
Volume	57
Issue number	5
DOIs	https://doi.org/10.1038/s41409-022-01616-7
State	Published - May 2022

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/s41409-022-01616-7

Cite this

@article{a27e096ef7444b0fb0cedb9805b1805e,

title = "Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?",

author = "Fareed Khawaja and Chemaly, {Roy F.}",

note = "Funding Information: RFC serves a scientific consultant/adviser for Merck, Ansun Biopharma, Takeda/Shire, Oxford Immunotec, ADMA Biologics, Pulmotec, Enanta, ReViral, and Genentech, and received research funding from Merck, Takeda/Shire, Oxford Immunotec, AiCuris, Ansun Biopharma, Viracor, Karius, Genentech, and Janssen. FK has none to report. ",

year = "2022",

month = may,

doi = "10.1038/s41409-022-01616-7",

language = "English (US)",

volume = "57",

pages = "701--702",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections

T2 - where are we now?

AU - Khawaja, Fareed

AU - Chemaly, Roy F.

N1 - Funding Information: RFC serves a scientific consultant/adviser for Merck, Ansun Biopharma, Takeda/Shire, Oxford Immunotec, ADMA Biologics, Pulmotec, Enanta, ReViral, and Genentech, and received research funding from Merck, Takeda/Shire, Oxford Immunotec, AiCuris, Ansun Biopharma, Viracor, Karius, Genentech, and Janssen. FK has none to report.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85125276175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125276175&partnerID=8YFLogxK

U2 - 10.1038/s41409-022-01616-7

DO - 10.1038/s41409-022-01616-7

M3 - Comment/debate

C2 - 35220411

AN - SCOPUS:85125276175

SN - 0268-3369

VL - 57

SP - 701

EP - 702

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 5

ER -

Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this